Vascular endothelial growth factor A (VEGF-A) decreases expression and secretion of pleiotrophin in a VEGF receptor-independent manner

Vascular Pharmacology

Volumn 80, Issue , 2016, Pages 11-19

  Poimenidi, Evangelia ^a,b   Theodoropoulou, Christina ^a   Koutsioumpa, Marina ^a,d   Skondra, Lamprini ^a   Droggiti, Eirini ^a   van den Broek, Marloes ^b,c   Koolwijk, Pieter ^b   Papadimitriou, Evangelia ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c A Skin BV   (Netherlands)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiogenesis; Endothelial cells; Growth factors; Migration; Nucleolin; Receptor protein tyrosine phosphatase beta zeta

Indexed keywords

BETA3 INTEGRIN; BEVACIZUMAB; HEPARIN; MESSENGER RNA; PLEIOTROPHIN; PROTEIN TYROSINE PHOSPHATASE; RECEPTOR PROTEIN TYROSINE PHOSPHATASE BETA; RECEPTOR PROTEIN TYROSINE PHOSPHATASE ZETA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULOTROPIN 121; VASCULOTROPIN 165; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 2; VITRONECTIN RECEPTOR; CARRIER PROTEIN; CYTOKINE; LIGAND; PEPTIDE FRAGMENT; RECEPTOR LIKE PROTEIN TYROSINE PHOSPHATASE; VASCULAR ENDOTHELIAL GROWTH FACTOR A (138-165);

ANGIOGENESIS; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; RECEPTOR DOWN REGULATION; ANIMAL; CELL CULTURE TECHNIQUE; CELL MOTION; CHO CELL LINE; CRICETULUS; DRUG EFFECTS; GENE EXPRESSION; GENETICS; METABOLISM; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; SECRETION (PROCESS); SIGNAL TRANSDUCTION; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING;

ANIMALS; BEVACIZUMAB; BLOTTING, WESTERN; CARRIER PROTEINS; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL MOVEMENT; CHO CELLS; CRICETULUS; CYTOKINES; GENE EXPRESSION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LIGANDS; PEPTIDE FRAGMENTS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR CROSS-TALK; RECEPTOR-LIKE PROTEIN TYROSINE PHOSPHATASES, CLASS 5; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84975689766     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2016.02.008     Document Type: Article

References (34)

1. Kieran M.W., Kalluri R., Cho Y.J. The VEGF pathway in cancer and disease: responses, resistance, and the path forward. Cold Spring Harb. Perspect. Med. 2012, 2:a006593. 10.1101/cshperspect.a006593.
2. Shibuya M., Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp. Cell Res. 2006, 312:549-560. 10.1016/j.yexcr.2005.11.012.
3. Koch S., Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Cold Spring Harb. Perspect. Med. 2012, 2:a006502. 10.1101/cshperspect.a006502.
4. Mahabeleshwar G.H., Feng W., Reddy K., Plow E.F., Byzova T.V. Mechanisms of integrin-vascular endothelial growth factor receptor cross-activation in angiogenesis. Circ. Res. 2007, 101:570-580. 10.1161/CIRCRESAHA.107.155655.
5. Koutsioumpa M., Poimenidi E., Pantazaka E., Theodoropoulou C., Skoura A., Megalïoikonomou V., et al. Receptor protein tyrosine phosphatase beta/zeta is a functional binding partner for vascular endothelial growth factor. Mol. Cancer 2015, 14:19. 10.1186/s12943-015-0287-3.
6. Pantazaka E., Papadimitriou E. Chondroitin sulfate-cell membrane effectors as regulators of growth factor-mediated vascular and cancer cell migration. Biochim. Biophys. Acta 1840, 2014:2643-2650. 10.1016/j.bbagen.2014.01.009.
7. Papadimitriou E., Mikelis C., Lampropoulou E., Koutsioumpa M., Theochari K., Tsirmoula S., et al. Roles of pleiotrophin in tumor growth and angiogenesis. Eur. Cytokine Netw. 2009, 20:180-190. 10.1684/ecn.2009.0172.
8. Pantazaka E., Papadimitriou E. PTN (pleiotrophin). Atlas Genet. Cytogenet. Oncol. Haematol. 2012, 16:821-837. 10.4267/2042/48231.
9. Nandi S., Cioce M., Yeung Y.G., Nieves E., Tesfa L., Lin H., et al. Receptor-type protein-tyrosine phosphatase ζ is a functional receptor for interleukin-34. J. Biol. Chem. 2013, 288:21972-21986. 10.1074/jbc.M112.442731.
10. 3 integrin and nucleolin regulates human endothelial and glioma cell migration. J. Biol. Chem. 2013, 288:343-354. 10.1074/jbc.M112.387076.
11. Koutsioumpa M., Papadimitriou E. Cell surface nucleolin as a target for anti-cancer therapies. Recent Pat. Anticancer Drug Discov. 2014, 9:137-152. 10.2174/1574892808666131119095953.
12. Mikelis C., Sfaelou E., Koutsioumpa M., Kieffer N., Papadimitriou E. Integrin alpha(v)beta(3) is a pleiotrophin receptor required for pleiotrophin-induced endothelial cell migration through receptor protein tyrosine phosphatase beta/zeta. FASEB J. 2009, 23:1459-1469. 10.1096/fj.08-117564.
13. Poimenidi E., Hatziapostolou M., Papadimitriou E. Serum stimulates pleiotrophin gene expression in an AP-1-dependent manner in human endothelial and glioblastoma cells. Anticancer Res. 2009, 29:349-354.
14. Wong M.L., Medrano J.F. Real-time PCR for mRNA quantitation. Biotechniques 2005, 39:75-85.
15. Polytarchou C., Hatziapostolou M., Papadimitriou E. Hydrogen peroxide stimulates proliferation and migration of human prostate cancer cells through activation of activator protein-1 and up-regulation of the heparin affin regulatory peptide gene. J. Biol. Chem. 2005, 280:40428-40435. 10.1074/jbc.M505120200.
16. Grzelinski M., Urban-Klein B., Martens T., Lamszus K., Bakowsky U., Höbel S., et al. RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Hum. Gene Ther. 2006, 17:751-766.
17. Polykratis A., Katsoris P., Courty J., Papadimitriou E. Characterization of heparin affin regulatory peptide signaling in human endothelial cells. J. Biol. Chem. 2005, 280:22454-22461. 10.1074/jbc.M414407200.
18. Wang Y., Fei D., Vanderlaan M., Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 2004, 7:335-345. 10.1007/s10456-004-8272-2.
19. Destouches D., El Khoury D., Hamma-Kourbali Y., Krust B., Albanese P., Katsoris P., et al. Suppression of tumor growth and angiogenesis by a specific antagonist of the cell-surface expressed nucleolin. PLoS One 2008, 3. 10.1371/journal.pone.0002518.
20. Héroult M., Bernard-Pierrot I., Delbé J., Hamma-Kourbali Y., Katsoris P., Barritault D., et al. Heparin affin regulatory peptide binds to vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. Oncogene 2004, 23:1745-1753. 10.1038/sj.onc.1206879.
21. Kong Y., Bai P.S., Nan K.J., Sun H., Chen N.Z., Qi X.G. Pleiotrophin is a potential colorectal cancer prognostic factor that promotes VEGF expression and induces angiogenesis in colorectal cancer. Int. J. Color. Dis. 2012, 27:287-298. 10.1007/s00384-011-1344-z.
22. Koutsioumpa M., Drosou G., Mikelis C., Theochari K., Vourtsis D., Katsoris P., et al. Pleiotrophin expression and role in physiological angiogenesis in vivo: potential involvement of nucleolin. Vasc. Cell 2012, 4:4. 10.1186/2045-824X-4-4.
23. Liu J., Wu X., Liu Y., Xu Y., Huang Y., Xing C., et al. High-glucose-based peritoneal dialysis solution induces the upregulation of VEGF expression in human peritoneal mesothelial cells: the role of pleiotrophin. Int. J. Mol. Med. 2013, 32:1150-1158. 10.3892/ijmm.2013.1491.
24. Zhu X., Bai Y., Yu W., Pan C., Jin E., Song D., et al. The effects of pleiotrophin in proliferative diabetic retinopathy. PLoS One 2015, 10. 10.1371/journal.pone.0115523.
25. Zhang L., Kundu S., Feenstra T., Li X., Jin C., Laaniste L., et al. Pleiotrophin promotes vascular abnormalization in gliomas and correlates with poor survival in patients with astrocytomas. Sci. Signal. 2015, 8(406):ra125. 10.1126/scisignal.aaa1690.
26. Verheul H.M., Lolkema M.P., Qian D.Z., Hilkes Y.H., Liapi E., Akkerman J.W., et al. Platelets take up the monoclonal antibody bevacizumab. Clin. Cancer Res. 2007, 13:5341-5347. 10.1158/1078-0432.CCR-07-0847.
27. Deissler H.L., Lang G.K., Lang G.E. Internalization of bevacizumab by retinal endothelial cells and its intracellular fate: evidence for an involvement of the neonatal Fc receptor. Exp. Eye Res. 2015, 143:49-59. 10.1016/j.exer.2015.10.007.
28. Aboul Naga S.H., Dithmer M., Chitadze G., Kabelitz D., Lucius R., Roider J., et al. Intracellular pathways following uptake of bevacizumab in RPE cells. Exp. Eye Res. 2015, 131:29-41. 10.1016/j.exer.2014.12.010.
29. Guangqi E., Cao Y., Bhattacharya S., Dutta S., Wang E., Mukhopadhyay D. Endogenous vascular endothelial growth factor-A (VEGF-A) maintains endothelial cell homeostasis by regulating VEGF receptor-2 transcription. J. Biol. Chem. 2012, 287(5):3029-3041. 10.1074/jbc.M111.293985.
30. Losfeld M.E., Khoury D.E., Mariot P., Carpentier M., Krust B., Briand J.P., et al. The cell surface expressed nucleolin is a glycoprotein that triggers calcium entry into mammalian cells. Exp. Cell Res. 2009, 315:357-369. 10.1016/j.yexcr.2008.10.039.
31. Samuel S., Twizere J.C., Beifuss K.K., Bernstein L.R. Nucleolin binds specifically to an AP-1 DNA sequence and represses AP1-dependent transactivation of the matrix metalloproteinase-13 gene. Mol. Carcinog. 2008, 47:34-46. 10.1002/mc.20358.
32. Fähling M., Steege A., Perlewitz A., Nafz B., Mrowka R., Persson P.B., et al. Role of nucleolin in posttranscriptional control of MMP-9 expression. Biochim. Biophys. Acta 1731, 2005:32-40. 10.1016/j.bbaexp.2005.08.005.
33. Uribe D.J., Guo K., Shin Y.J., Sun D. Heterogeneous nuclear ribonucleoprotein K and nucleolin as transcriptional activators of the vascular endothelial growth factor promoter through interaction with secondary DNA structures. Biochemistry 2011, 50:3796-3806. 10.1021/bi101633b.
34. D'Amico G., Robinson S.D., Germain M., Reynolds L.E., Thomas G.J., Elia G., et al. Endothelial-Rac1 is not required for tumor angiogenesis unless alphavbeta3-integrin is absent. PLoS One 2010, 5. 10.1371/journal.pone.0009766.